Chronic neuroblastoma: Indolent stage 4 disease in children

Cancer

Volumn 95, Issue 6, 2002, Pages 1366-1375

  Kushner, Brian H ^a   Kramer, Kim ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biologic therapy; Chemotherapy; Chronic disease; Indolent disease; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IODINE 131; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GD2; MYELOABLATIVE AGENT; RETINOIC ACID; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; INFANT; MALE; NEUROBLASTOMA; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; TOXICITY; TREATMENT OUTCOME; CHILD; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; REMISSION; TUMOR RECURRENCE;

CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFANT; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; REMISSION INDUCTION;

EID: 0037105539     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10800     Document Type: Article

References (54)

1. Biology and treatment of neuroblastoma
2. Neuroblastoma: Biology and therapy
3. Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution
4. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
5. Multiagent chemotherapy for children with metastatic neuroblastoma: A report from the childrens cancer study group
6. Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis
7. Neuroblastoma in adults and adolescents. An indolent course with poor survival
8. Models to predict outcome from childhood neuroblastoma: The role of serum ferritin and tumor histology
9. Serum lactate dehydrogenase in childhood neuroblastoma
10. Osseous metastases in neuroblastoma. A 17-year survival
11. Recrudescence of neuroblastoma after apparent cure
12. Late recurrence of neuroblastoma: A report of five cases and review of the literature
13. Long-term survival in refractory recurrent neuroblastoma
14. Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: A report from the European neuroblastoma study group "Survey"
15. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
16. Stage IV-N: A favorable subset of children with metastatic neuroblastoma
17. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma
18. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors
19. Efficacy of palliative oral etoposide in metastatic neuroblastoma relapsing after high-dose chemotherapy
20. Oral etoposide for refractory and relapsed neuroblastoma
21. Aggressive treatment of neuroblastoma
22. Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults
23. Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: Experience with 100 patients
24. Excellent results of the use of ifosfamide, carboplatin, etoposide (I.C.E.) in children with recurrent or refractory solid tumors
25. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A pediatric oncology group study
26. Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study
27. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma
28. Escalating doses of continuous infusion combination chemotherapy for refractory neuroblastoma
29. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age
30. Chemotherapy for patients with recurrent or refractory neuroblastoma: A POG phase II study
31. N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age
32. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors
33. D2 anti-body treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
34. D2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
35. Hyperfractionated low-dose radiotherapy (21 Gy) for high-risk neuroblastoma after intensive chemotherapy and surgery
36. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma
37. Neuroblastoma, its natural history and prognosis: A study of 487 cases
38. Neuroblastoma: Review of the literature and an examination of factors contributing to its enigmatic character
39. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St Jude children's research hospital experience, 1962-1988
40. Clinical prognostic factors in 1277 patients with neuroblastoma: Results of the European neuroblastoma study group "survey"
41. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: A report from the European group for bone marrow transplantation
42. A phase I pharmacokinetic study of fenretinide (HPR) in children with high-risk solid tumors. A childrens cancer group (CCG) study
43. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma
44. IL-2 adenovirus-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma
45. A pilot study of anti-idiotype monoclonal antibody as tumor vaccine in patients with high-risk neuroblastoma
46. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression
47. 131I-metaiodobenzyl-guanidine with autologous bone marrow support in refractory neuroblastoma
48. LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis
49. Stage 4 neuroblastoma diagnosed at more than 1 year of age: Gross total resection and clinical outcome
50. Second complete remissions (CR) in children with metastatic neuroblastoma (NB)
51. The recurrence patterns of stages I, II, and III neuroblastoma: Experience with 77 relapsing patients
52. N-myc amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL 90 Study
53. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells
54. Monoclonal anti-body-based therapy of neuroblastoma